All patients with concurrent presence of BCR::ABL1 and JAK2 V617F (JAK2 V617Fpos/BCR::ABL1pos) gave written informed consent to be included in the German Registry of Eosinophils, Mast Cells and rare myeloid neoplasms. Here, JAK2 is linked to myeloid neoplasm.